Fig. 3From: Endothelial function measured by peripheral arterial tonometry in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy: a pilot studyComparison of the reactive hyperemia index (RHI) between patients receiving imatinib and those receiving second- or third-generation TKIs. No difference is seen between imatinib and newer TKIs in terms of the RHIBack to article page